Should You Buy Tilray Brands Stock Before Oct. 9?
By David Jagielski | October 4, 2025
Tilray Brands (TLRY) has been making waves lately. Recently, its stock price has shot up nearly 300% since July, driven by buzz around potential marijuana reform in the U.S. But before you jump on the hype train, let’s dig into whether now's the right time to invest and what investors should keep an eye on as Tilray approaches its earnings report on Oct. 9.
What's Happening with Tilray?
Tilray has been in the spotlight due to excitement around possible cannabis reform, leading many investors to believe there’s growth on the horizon for this Canadian cannabis producer. However, let’s not forget that just because there’s hype doesn’t mean there’s solid groundwork beneath it.
The Cold, Hard Facts
Despite the recent rally, Tilray hasn’t had a smooth ride. Its fundamentals are rocky, and the company has struggled to turn a profit. Many investors are anxiously waiting to see if the upcoming earnings report will provide any positive surprises.
But here's the kicker: Tilray's earnings reports haven’t typically spurred positive momentum for the stock. Instead, there might even be selling pressure following the release of the results.
A Quick Look at Tilray's Performance
Tilray's financial history is a mixed bag. Although it ended its last fiscal year, which concluded in May, with revenues of around $821.3 million (a modest 4% year-over-year boost), its core cannabis segment actually saw a 9% decline. That's not a great sign for a company mostly known for its cannabis products.
Plus, while Tilray has diversified into alcohol and wellness products, helping pad its revenue, this doesn’t mask the ongoing issues. It reported an operating loss of $174.7 million last year, a significant improvement from the previous year's staggering $2.1 billion loss, but this doesn’t entirely alleviate concerns over its financial health.
Why Be Cautious?
The cannabis market is incredibly competitive, and Tilray is constantly facing challenges that make it tough to stand out. With no real clarity on U.S. marijuana reform and the excitement often leading to disappointment, this stock comes with high risks.
Many investors have heard about potential legalization for years, yet little has materialized. When expectations run high, Tilray’s stock price tends to soar, but it can plummet just as quickly when the reality sets in.
Final Thoughts: Is It Worth the Gamble?
For now, betting on Tilray could be a risky move. The combination of a speculative stock and tough competition paints a picture of uncertainty. If you're thinking about buying into the hype for Tilray ahead of its upcoming earnings report, you might want to think again.
About the Author
David Jagielski is a CPA and contributing analyst at The Motley Fool, specializing in stocks in healthcare, technology, and consumer goods. With over a decade of finance experience, David has his finger on the pulse of the market.
Disclaimer: Always do your research before making investment decisions. Past performance doesn’t guarantee future success.
Comments
Post a Comment